Solara Active Pharma Sciences · NSE: SOLARA · BSE: 541540
Q3 FY22 results · Oct–Dec 2021
Solara Active Pharma Sciences reported revenue from operations of ₹100.34 crore (down 76.5% from Q3 FY21) and net loss of ₹139.89 crore for Q3 FY22 (Oct–Dec 2021), on a consolidated basis.
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 100.34 | 426.69 | −76.5% | 401.61 | −75.0% |
| Other income | 4.73 | 8.29 | −42.9% | 3.31 | +42.9% |
| Total income | 105.07 | 434.98 | −75.8% | 404.92 | −74.1% |
| Profit before tax | (139.89) | 65.79 | Turned loss | 29.68 | Turned loss |
| Net profit for the period | (139.89) | 65.78 | Turned loss | 29.68 | Turned loss |
| Attributable to shareholders of the company | (139.87) | — | — | 29.71 | Turned loss |
| EPS, basic (₹) | (38.93) | 18.47 | Turned loss | 8.27 | Turned loss |
| Net margin (%) | -139.4 | 15.4 | 7.4 |
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 100.34 | 426.69 | −76.5% | 401.61 | −75.0% |
| Other income | 4.76 | 8.29 | −42.6% | 3.51 | +35.6% |
| Total income | 105.10 | 434.98 | −75.8% | 405.12 | −74.1% |
| Profit before tax | (139.57) | 65.78 | Turned loss | 30.23 | Turned loss |
| Net profit for the period | (139.57) | 65.78 | Turned loss | 30.23 | Turned loss |
| EPS, basic (₹) | (38.85) | 18.48 | Turned loss | 8.42 | Turned loss |
| Net margin (%) | -139.1 | 15.4 | 7.5 |
Consolidated
- Filed with BSE
- 09 Feb 2022, 19:01 IST
- Board meeting
- 09 Feb 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 09 Feb 2022, 19:01 IST
- Board meeting
- 09 Feb 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE